Key Highlights
- SPY001 produced clinical remission in 40% and endoscopic improvement in 51% of ulcerative colitis patients in the open-label Part A of the SKYLINE Phase 2 trial.
- SPY002 showed 33% clinical remission and SPY003 showed 20%, with all three antibodies meeting the primary endpoint of a lower Robarts Histopathology index score.
- SPY072 failed the primary endpoints in both psoriatic arthritis and axial spondyloarthritis, and the company does not plan to advance it in rheumatic diseases.
- Randomized Part B induction data from SKYLINE are expected in the third quarter of 2027, and SPY072 pivotal studies in hidradenitis suppurativa are planned for 2027.
SKYLINE Part A Results Detailed in the 10-Q
Spyre Therapeutics (NASDAQ:SYRE) filed its Quarterly Report for the period ended September 30, 2026 on November 3, 2026. The company is a clinical-stage biotechnology firm developing extended half-life antibodies against targets including alpha4beta7, TL1A, IL-23 and IL-17A/F for immune-mediated diseases. In Part A of its SKYLINE Phase 2 trial in ulcerative colitis, SPY001, SPY002 and SPY003 each met the primary endpoint, with reductions in the Robarts Histopathology Index of 9.2, 10.7 and 10.0 points. Clinical remission was 40%, 33% and 20%, and endoscopic improvement was 51%, 42% and 30%, respectively. The induction data cutoff was July 27, 2026, with database lock on August 27, 2026, and the change in the modified Mayo Score at Week 12 was minus 3.7 for SPY001 and SPY002 and minus 3.5 for SPY003.
Open-Label Data, Combination Plans and the HS Bet
Part A was open-label and tested one dose of each single agent, so it carried no placebo group, and the numbers should not be compared directly with other companies' trials. The company's thesis is that pairing mechanisms, such as SPY120 (alpha4beta7 plus TL1A), SPY130 (alpha4beta7 plus IL-23) and SPY230 (TL1A plus IL-23), can deliver more complete disease control. Part B is randomized and placebo-controlled, is enrolling ahead of schedule with a higher enrollment target, and will report induction data in the third quarter of 2027. In hidradenitis suppurativa, the SKYLIGHT trial began in September 2026 with topline results planned for late 2027 or early 2028.
Rheumatic Disease Setback and Risks Ahead
The filing also records a setback. In rheumatoid arthritis, SPY072 beat placebo on several endpoints in August 2026, but the company said the results did not meet its internal bar to prioritize that indication. In November 2026 it announced that the psoriatic arthritis and axial spondyloarthritis sub-studies missed their primary endpoints, although SPY072 was well tolerated, and it will not pursue rheumatic diseases. The extract reviewed here did not include cash, net loss or runway figures, so funding needs for the 2027 readouts cannot be assessed. Combination programs also remain unproven in controlled trials, and any Part B miss could reset expectations.
Where Things Stand
The 40% figure is encouraging but early: it comes from an open-label single-agent cohort, not from a randomized combination study. Spyre Therapeutics (NASDAQ:SYRE) has shown that all three antibodies met their primary histology endpoint with a safety profile consistent with in-class comparators, while SPY072 was dropped from rheumatic diseases. The decisive data are the placebo-controlled Part B results expected in the third quarter of 2027 and the HS readout around late 2027 or early 2028. Until then, cash and trial execution are the main variables, and cash figures were not in the supplied extract.






Please wait processing your request...